Cerebral Ischemia and Inflammation

Stroke

Volumn , Issue , 2011, Pages 138-153

  Iadecola, Costantino ^a   Abe, Takato ^a   Kunz, Alexander ^a   Hallenbeck, John ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882835000     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5478-8.10009-0     Document Type: Chapter

References (239)

1. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
2. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2:734-744.
3. Emerich D.F., Dean R.L., Bartus R.T. The role of leukocytes following cerebral ischemia: Pathogenic variable or bystander reaction to emerging infarct?. Exp Neurol 2002, 173:168-181.
4. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. J Neuroimmunol 2007, 184:53-68.
5. Wunder A., Klohs J., Dirnagl U. Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience 2009, 158:1161-1173.
6. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999, 19:819-834.
7. Frijns C.J., Kappelle L.J. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002, 33:2115-2122.
8. Ogata J., Yamanishi H., Pantoni L. Chapter 5 neuropathology of ischemic brain injury. Handb Clin Neurol 2008, 92:93-116.
9. Kostulas N., Pelidou S.H., Kivisakk P., Kostulas V., Link H. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999, 30:2174-2179.
10. Pelidou S.H., Kostulas N., Matusevicius D., Kivisakk P., Kostulas V., Link H. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol 1999, 6:437-442.
11. Suzuki S., Tanaka K., Suzuki N. Ambivalent aspects of interleukin-6 in cerebral ischemia: Inflammatory versus neurotrophic aspects. J Cereb Blood Flow Metab 2009, 29:464-479.
12. del Zoppo G., Ginis I., Hallenbeck J.M., Iadecola C., Wang X., Feuerstein G.Z. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000, 10:95-112.
13. Ritter L.S., Orozco J.A., Coull B.M., McDonagh P.F., Rosenblum W.I. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. Stroke 2000, 31:1153-1161.
14. Peters E.E., Feuerstein G.Z. Chemokines and ischemic stroke. Inflammation and stroke 2001, 155-162. Birkhauser, New York. G.Z. Feuerstein (Ed.).
15. Heinel L.A., Rubin S., Rosenwasser R.H., Vasthare U.S., Tuma R.F. Leukocyte involvement in cerebral infarct generation after ischemia and reperfusion. Brain Res Bull 1994, 34:137-141.
16. Matsuo Y., Onodera H., Shiga Y., Nakamura M., Ninomiya M., Kihara T., Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Stroke 1994, 25:1469-1475.
17. Jiang N., Moyle M., Soule H.R., Rote W.E., Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol 1995, 38:935-942.
18. Zhang R.L., Chopp M., Li Y., Zaloga C., Jiang N., Jones M.L., Miyasaka M., Ward P.A. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994, 44:1747-1751.
19. Mori E., del Zoppo G.J., Chambers J.D., Copeland B.R., Arfors K.E. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 1992, 23:712-718.
20. Chen H., Chopp M., Zhang R.L., Bodzin G., Chen Q., Rusche J.R., Todd R.F. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol 1994, 35:458-463.
21. Zhang R.L., Chopp M., Zhang Z.G., Phillips M.L., Rosenbloom C.L., Cruz R., Manning A. E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab 1996, 16:1126-1136.
22. Morikawa E., Zhang S.M., Seko Y., Toyoda T., Kirino T. Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Stroke 1996, 27:951-955.
23. Suzuki H., Hayashi T., Tojo S.J., Kitagawa H., Kimura K., Mizugaki M., Itoyama Y., Abe K. Anti-P-selectin antibody attenuates rat brain ischemic injury. Neurosci Lett 1999, 265:163-166.
24. Connolly E.S., Winfree C.J., Prestigiacomo C.J., Kim S.C., Choudhri T.F., Hoh B.L., Naka Y., Solomon R.A., Pinsky D.J. Exacerbation of cerebral injury in mice that express the P-selectin gene: Identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997, 81:304-310.
25. Soriano S.G., Coxon A., Wang Y.F., Frosch M.P., Lipton S.A., Hickey P.R., Mayadas T.N. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke 1999, 30:134-139.
26. Connolly E.S., Winfree C.J., Springer T.A., Naka Y., Liao H., Yan S.D., Stern D.M., Solomon R.A., Gutierrez-Ramos J.C., Pinsky D.J. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996, 97:209-216.
27. Dawson D.A., Martin D., Hallenbeck J.M. Inhibition of tumor necrosis factor-alpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci Lett 1996, 218:41-44.
28. Yang G.Y., Gong C., Qin Z., Ye W., Mao Y., Betz A.L. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 1998, 9:2131-2134.
29. Yamasaki Y., Matsuura N., Shozuhara H., Onodera H., Itoyama Y., Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995, 26:676-680.
30. Loddick S.A., Rothwell N.J. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1996, 16:932-940.
31. Loddick S.A., Turnbull A.V., Rothwell N.J. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998, 18:176-179.
32. Yang G.Y., Schielke G.P., Gong C., Mao Y., Ge H.L., Liu X.H., Betz A.L. Expression of tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interleukin-1beta converting enzyme deficient mice. J Cereb Blood Flow Metab 1999, 19:1109-1117.
33. Matsumoto T., Ikeda K., Mukaida N., Harada A., Matsumoto Y., Yamashita J., Matsushima K. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 1997, 77:119-125.
34. Yamasaki Y., Matsuo Y., Zagorski J., Matsuura N., Onodera H., Itoyama Y., Kogure K. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res 1997, 759:103-111.
35. Del Zoppo G.J., Schmid-Schonbein G.W., Mori E., Copeland B.R., Chang C.M. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991, 22:1276-1283.
36. Yilmaz G., Arumugam T.V., Stokes K.Y., Granger D.N. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006, 113:2105-2112.
37. Ahmed S.H., He Y.Y., Nassief A., Xu J., Xu X.M., Hsu C.Y., Faraci F.M. Effects of lipopolysaccharide priming on acute ischemic brain injury. Stroke 2000, 31:193-199.
38. Becker K., Kindrick D., Relton J., Harlan J., Winn R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001, 32:206-211.
39. Relton J.K., Sloan K.E., Frew E.M., Whalley E.T., Adams S.P., Lobb R.R. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke 2001, 32:199-205.
40. Prestigiacomo C.J., Kim S.C., Connolly E.S., Liao H., Yan S.F., Pinsky D.J. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999, 30:1110-1117.
41. Arumugam T.V., Salter J.W., Chidlow J.H., Ballantyne C.M., Kevil C.G., Granger D.N. Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004, 287:H2555-2560.
42. Campanella M., Sciorati C., Tarozzo G., Beltramo M. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002, 33:586-592.
43. Hurn P.D., Subramanian S., Parker S.M., Afentoulis M.E., Kaler L.J., Vandenbark A.A., Offner H. T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab 2007, 27:1798-1805.
44. Liesz A., Suri-Payer E., Veltkamp C., Doerr H., Sommer C., Rivest S., Giese T., Veltkamp R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009, 15:192-199.
45. Planas A.M., Chamorro A. Regulatory T cells protect the brain after stroke. Nat Med 2009, 15:138-139.
46. Buttini M., Sauter A., Boddeke H.W. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 1994, 23:126-134.
47. Liu T., McDonnell P.C., Young P.R., White R.F., Siren A.L., Hallenbeck J.M., Barone F.C., Feurestein G.Z. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 1993, 24:1746-1750.
48. Liu T., Clark R.K., McDonnell P.C., Young P.R., White R.F., Barone F.C., Feuerstein G.Z. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25:1481-1488.
49. Wang X., Yue T.L., Barone F.C., White R.F., Gagnon R.C., Feuerstein G.Z. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 1994, 23:103-114.
50. Minami M., Kuraishi Y., Yabuuchi K., Yamazaki A., Satoh M. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem 1992, 58:390-392.
51. Yabuuchi K., Minami M., Katsumata S., Yamazaki A., Satoh M. An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain. Brain Res Mol Brain Res 1994, 26:135-142.
52. Saito K., Suyama K., Nishida K., Sei Y., Basile A.S. Early increases in TNF-alpha, IL-6 and IL-1 beta levels following transient cerebral ischemia in gerbil brain. Neurosci Lett 1996, 206:149-152.
53. Uno H., Matsuyama T., Akita H., Nishimura H., Sugita M. Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab 1997, 17:491-499.
54. Barone F.C., Arvin B., White R.F., Miller A., Webb C.L., Willette R.N., Lysko P.G., Feuerstein G.Z. Tumor necrosis factor-alpha: A mediator of focal ischemic brain injury. Stroke 1997, 28:1233-1244.
55. Garcia J.H., Liu K.F., Relton J.K. Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol 1995, 147:1477-1486.
56. Relton J.K., Rothwell N.J. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29:243-246.
57. Rothwell N.J., Relton J.K. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev 1993, 5:178-198.
58. Martin D., Chinookoswong N., Miller G. The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp Neurol 1994, 130:362-367.
59. Betz A.L., Yang G.Y., Davidson B.L. Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995, 15:547-551.
60. Basu A., Krady J.K., O'Malley M., Styren S.D., DeKosky S.T., Levison S.W. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J Neurosci 2002, 22:6071-6082.
61. Iadecola C., Salkowski C.A., Zhang F., Aber T., Nagayama M., Vogel S.N., Ross M.E. The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med 1999, 189:719-727.
62. Arumugam T.V., Granger D.N., Mattson M.P. Stroke and T-cells. Neuromolecular Med 2005, 7:229-242.
63. Liu J., Ginis I., Spatz M., Hallenbeck J.M. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol 2000, 278:C144-153.
64. Bruce A.J., Boling W., Kindy M.S., Peschon J., Kraemer P.J., Carpenter M.K., Holtsberg F.W., Mattson M.P. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996, 2:788-794.
65. Yang L., Lindholm K., Konishi Y., Li R., Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002, 22:3025-3032.
66. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22:RC216.
67. Martin-Villalba A., Hahne M., Kleber S., Vogel J., Falk W., Schenkel J., Krammer P.H. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001, 8:679-686.
68. Becker K.J. Sensitization and tolerization to brain antigens in stroke. Neuroscience 2009, 158:1090-1097.
69. Prass K., Meisel C., Hoflich C., Braun J., Halle E., Wolf T., Ruscher K., Victorov I.V., Priller J., Dirnagl U., Volk H.D., Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003, 198:725-736.
70. Meisel C., Schwab J.M., Prass K., Meisel A., Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005, 6:775-786.
71. Murphy S., Gibson C.L. Nitric oxide, ischaemia and brain inflammation. Biochem Soc Trans 2007, 35:1133-1137.
72. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 2008, 27:2783-2802.
73. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87:1620-1624.
74. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
75. Iadecola C., Zhang F., Xu X., Casey R., Ross M.E. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995, 15:378-384.
76. Iadecola C., Zhang F., Casey R., Clark H.B., Ross M.E. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996, 27:1373-1380.
77. Grandati M., Verrecchia C., Revaud M.L., Allix M., Boulu R.G., Plotkine M. Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. Br J Pharmacol 1997, 122:625-630.
78. Hirabayashi H., Takizawa S., Fukuyama N., Nakazawa H., Shinohara Y. Nitrotyrosine generation via inducible nitric oxide synthase in vascular wall in focal ischemia-reperfusion. Brain Res 2000, 852:319-325.
79. Forster C., Clark H.B., Ross M.E., Iadecola C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol 1999, 97:215-220.
80. Tarkowski E., Ringqvist A., Rosengren L., Jensen C., Ekholm S., Wennmalm A. Intrathecal release of nitric oxide and its relation to final brain damage in patients with stroke. Cerebrovasc Dis 2000, 10:200-206.
81. Iadecola C., Zhang F., Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995, 268:R286-R292.
82. Nagayama M., Zhang F., Iadecola C. Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J Cereb Blood Flow Metab 1998, 18:1107-1113.
83. Parmentier S., Bohme G.A., Lerouet D., Damour D., Stutzmann J.M., Margaill I., Plotkine M. Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 1999, 127:546-552.
84. Zhao X., Haensel C., Araki E., Ross M.E., Iadecola C. Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 2000, 872:215-218.
85. Iadecola C., Zhang F., Casey R., Nagayama M., Ross M.E. Delayed reduction in ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997, 17:9157-9164.
86. Parmentier-Batteur S., Bohme G.A., Lerouet D., Zhou-Ding L., Beray V., Margaill I., Plotkine M. Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J Cereb Blood Flow Metab 2001, 21:15-21.
87. Han H.S., Qiao Y., Karabiyikoglu M., Giffard R.G., Yenari M.A. Influence of mild hypothermia on inducible nitric oxide synthase expression and reactive nitrogen production in experimental stroke and inflammation. J Neurosci 2002, 22:3921-3928.
88. Coughlan T., Gibson C., Murphy S. Modulatory effects of progesterone on inducible nitric oxide synthase expression in vivo and in vitro. J Neurochem 2005, 93:932-942.
89. Park E.M., Cho S., Frys K.A., Glickstein S.B., Zhou P., Anrather J., Ross M.E., Iadecola C. Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury. J Cereb Blood Flow Metab 2006, 26:392-401.
90. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120.
91. Phillis J.W., Horrocks L.A., Farooqui A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res Rev 2006, 52:201-243.
92. Hurley S.D., Olschowka J.A., O'Banion M.K. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 2002, 19:1-15.
93. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem 2007, 42:127-141.
94. Miettinen S., Fusco F.R., Yrjanheikki J., Keinanen R., Hirvonen T., Roivainen R., Narhi M., Hokfelt T., Koistinaho J. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-d-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci U S A 1997, 94:6500-6505.
95. Nogawa S., Zhang F., Ross M.E., Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997, 17:2746-2755.
96. Iadecola C., Forster C., Nogawa S., Clark H.B., Ross M.E. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 1999, 98:9-14.
97. Nogawa S., Forster C., Zhang F., Nagayama M., Ross M.E., Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci U S A 1998, 95:10966-10971.
98. Sairanen T., Ristimaki A., Karjalainen-Lindsberg M.L., Paetau A., Kaste M., Lindsberg P.J. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998, 43:738-747.
99. Nagayama M., Niwa K., Nagayama T., Ross M.E., Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates cerebral ischemic injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999, 19:1213-1219.
100. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S., Ross M.E. Reduced susceptibility to ischemic brain injury and NMDA-mediated neurotoxicity in cyclooxygenase-2 deficient mice. Proc Natl Acad Sci U S A 2001, 98:1294-1299.
101. Moskowitz M.A., Lo E.H., ladecola C. The science of stroke: Mechanisms in search of treatments. Neuron 2010, 67:181-198.
102. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4:399-415.
103. Candelario-Jalil E., Fiebich B.L. Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des 2008, 14:1401-1418.
104. Kunz A., Anrather J., Zhou P., Orio M., Iadecola C. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab 2007, 27:545-551.
105. Manabe Y., Anrather J., Kawano T., Niwa K., Zhou P., Ross M.E., Iadecola C. Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 2004, 55:668-675.
106. Kawano T., Anrather J., Zhou P., Park L., Wang G., Frys K.A., Kunz A., Cho S., Orio M., Iadecola C. Prostaglandin E(2) EP1 receptors: Downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12:225-229.
107. Ahmad A.S., Saleem S., Ahmad M., Dore S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006, 89:265-270.
108. Zhou P., Qian L., Chou T., Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 2008, 29:543-551.
109. Iadecola C., Gorelick P.B. The Janus face of cyclooxygenase-2 in ischemic stroke: Shifting toward downstream targets. Stroke 2005, 36:182-185.
110. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272-277.
111. Hallenbeck J.M., Frerichs K.U. Secondary ischemic neuronal damage may involve multiple factors acting as an aggregate of minor causes. Frontiers in cerebrovascular disease: Mechanisms, diagnosis, and treatment 1998, 95-101. Futura Publishing Company, Inc, Armonk, NY. J.T. Robertson, T.S. Nowak (Eds.).
112. Hallenbeck J.M., Frerichs K.U. Stroke therapy. It may be time for an integrated approach. Arch Neurol 1993, 50:768-770.
113. Iadecola C., Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001, 14:89-94.
114. Lee Y.J., Hallenbeck J.M. Insights into cytoprotection from ground squirrel hibernation, a natural model of tolerance to profound brain oligaemia. Biochem Soc Trans 2006, 34:1295-1298.
115. Oppenheim J.J., Yang D. Alarmins: Chemotactic activators of immune responses. Curr Opin Immunol 2005, 17:359-365.
116. Zedler S., Faist E. The impact of endogenous triggers on trauma-associated inflammation. Curr Opin Crit Care 2006, 12:595-601.
117. Lehrer R.I., Ganz T. Cathelicidins: A family of endogenous antimicrobial peptides. Curr Opin Hematol 2002, 9:18-22.
118. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., Lee M.H., Han P.L., Park J.S., Lee J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006, 26:6413-6421.
119. Foell D., Wittkowski H., Vogl T., Roth J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
120. Lin L. RAGE on the toll road?. Cell Mol Immunol 2006, 3:351-358.
121. Akira S., Takeda K., Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
122. Ishii K.J., Akira S. Potential link between the immune system and metabolism of nucleic acids. Curr Opin Immunol 2008, 20:524-529.
123. Jin M.S., Lee J.O. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008, 29:182-191.
124. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., Schroeder L., Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000, 97:13766-13771.
125. Horner A.A., Redecke V., Raz E. Toll-like receptor ligands: Hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol 2004, 4:555-561.
126. Arumugam T.V., Okun E., Tang S.C., Thundyil J., Taylor S.M., Woodruff T.M. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16.
127. Tang S.C., Arumugam T.V., Xu X., Cheng A., Mughal M.R., Jo D.G., Lathia J.D., Siler D.A., Chigurupati S., Ouyang X., Magnus T., Camandola S., Mattson M.P. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 2007, 104:13798-13803.
128. Ziegler G., Harhausen D., Schepers C., Hoffmann O., Rohr C., Prinz V., Konig J., Lehrach H., Nietfeld W., Trendelenburg G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 2007, 359:574-579.
129. Cao C.X., Yang Q.W., Lv F.L., Cui J., Fu H.B., Wang J.Z. Reduced cerebral ischemia-reperfusion injury in toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 2007, 353:509-514.
130. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
131. Lehnardt S., Lehmann S., Kaul D., Tschimmel K., Hoffmann O., Cho S., Krueger C., Nitsch R., Meisel A., Weber J.R. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007, 190:28-33.
132. Hua F., Ma J., Ha T., Xia Y., Kelley J., Williams D.L., Kao R.L., Browder I.W., Schweitzer J.B., Kalbfleisch J.H., Li C. Activation of toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J Neuroimmunol 2007, 190:101-111.
133. Park I.H., Yeon S.I., Youn J.H., Choi J.E., Sasaki N., Choi I.H., Shin J.S. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004, 40:1203-1211.
134. Zimmerman G.A., Meistrell M., Bloom O., Cockroft K.M., Bianchi M., Risucci D., Broome J., Farmer P., Cerami A., Vlassara H., et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995, 92:3744-3748.
135. Degryse B., Bonaldi T., Scaffidi P., Muller S., Resnati M., Sanvito F., Arrigoni G., Bianchi M.E. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001, 152:1197-1206.
136. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
137. Qiu J., Nishimura M., Wang Y., Sims J.R., Qiu S., Savitz S.I., Salomone S., Moskowitz M.A. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008, 28:927-938.
138. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., Bendszus M., Rossetti G., Nawroth P.P., Bierhaus A., Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008, 28:12023-12031.
139. Li M., Carpio D.F., Zheng Y., Bruzzo P., Singh V., Ouaaz F., Medzhitov R.M., Beg A.A. An essential role of the NF-kappaB/toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001, 166:7128-7135.
140. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007, 14:10-22.
141. Tabuchi M., Inoue K., Usui-Kataoka H., Kobayashi K., Teramoto M., Takasugi K., Shikata K., Yamamura M., Ando K., Nishida K., Kasahara J., Kume N., Lopez L.R., Mitsudo K., Nobuyoshi M., Yasuda T., Kita T., Makino H., Matsuura E. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007, 48:768-781.
142. Lamkanfi M., Declercq W., Vanden Berghe T., Vandenabeele P. Caspases leave the beaten track: Caspase-mediated activation of NF-kappaB. J Cell Biol 2006, 173:165-171.
143. Wuerzberger-Davis S.M., Nakamura Y., Seufzer B.J., Miyamoto S. NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene 2007, 26:641-651.
144. Silverstein R.L., Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009, 2:1-8.
145. Hirano K., Kuwasako T., Nakagawa-Toyama Y., Janabi M., Yamashita S., Matsuzawa Y. Pathophysiology of human genetic CD36 deficiency. Trends Cardiovasc Med 2003, 13:136-141.
146. Medeiros L.A., Khan T., El Khoury J.B., Pham C.L., Hatters D.M., Howlett G.J., Lopez R., O'Brien K.D., Moore K.J. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem 2004, 279:10643-10648.
147. Stuart L.M., Deng J., Silver J.M., Takahashi K., Tseng A.A., Hennessy E.J., Ezekowitz R.A., Moore K.J. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol 2005, 170:477-485.
148. Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S., Hartung T., Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem 2006, 281:31002-31011.
149. Cho S., Park E.M., Febbraio M., Anrather J., Park L., Racchumi G., Silverstein R.L., Iadecola C. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci 2005, 25:2504-2512.
150. Kunz A., Abe T., Hochrainer K., Shimamura M., Anrather J., Racchumi G., Zhou P., Iadecola C. Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J Neurosci 2008, 28:1649-1658.
151. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-96.
152. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
153. Hallenbeck J.M. The many faces of tumor necrosis factor in stroke. Nat Med 2002, 8:1363-1368.
154. Schwaninger M., Inta I., Herrmann O. NF-kappaB signalling in cerebral ischaemia. Biochem Soc Trans 2006, 34:1291-1294.
155. Blondeau N., Widmann C., Lazdunski M., Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci 2001, 21:4668-4677.
156. Pradillo J.M., Romera C., Hurtado O., Cardenas A., Moro M.A., Leza J.C., Davalos A., Castillo J., Lorenzo P., Lizasoain I. TNFR1 upregulation mediates tolerance after brain ischemic preconditioning. J Cereb Blood Flow Metab 2005, 25:193-203.
157. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730.
158. Vanden Berghe W., Ndlovu M.N., Hoya-Arias R., Dijsselbloem N., Gerlo S., Haegeman G. Keeping up NF-kappaB appearances: Epigenetic control of immunity or inflammation-triggered epigenetics. Biochem Pharmacol 2006, 72:1114-1131.
159. Baeuerle P.A., Baltimore D. NF-kappaB: Ten years after. Cell 1996, 87:13-20.
160. Salminen A., Liu P.K., Hsu C.Y. Alteration of transcription factor binding activities in the ischemic rat brain. Biochem Biophys Res Commun 1995, 212:939-944.
161. Carroll J.E., Hess D.C., Howard E.F., Hill W.D. Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?. Neuroreport 2000, 11:R1-4.
162. Gabriel C., Justicia C., Camins A., Planas A.M. Activation of nuclear factor-kappaB in the rat brain after transient focal ischemia. Brain Res Mol Brain Res 1999, 65:61-69.
163. Stephenson D., Yin T., Smalstig E.B., Hsu M.A., Panetta J., Little S., Clemens J. Transcription factor nuclear factor-kappaB is activated in neurons after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:592-603.
164. Schneider A., Martin-Villalba A., Weih F., Vogel J., Wirth T., Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999, 5:554-559.
165. Terai K., Matsuo A., McGeer E.G., McGeer P.L. Enhancement of immunoreactivity for NF-kappaB in human cerebral infarctions. Brain Res 1996, 739:343-349.
166. Nurmi A., Lindsberg P.J., Koistinaho M., Zhang W., Juettler E., Karjalainen-Lindsberg M.L., Weih F., Frank N., Schwaninger M., Koistinaho J. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 2004, 35:987-991.
167. Xu L., Zhan Y., Wang Y., Feuerstein G.Z., Wang X. Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. Biochem Biophys Res Commun 2002, 299:14-17.
168. Herrmann O., Baumann B., de Lorenzi R., Muhammad S., Zhang W., Kleesiek J., Malfertheiner M., Kohrmann M., Potrovita I., Maegele I., Beyer C., Burke J.R., Hasan M.T., Bujard H., Wirth T., Pasparakis M., Schwaninger M. IKK mediates ischemia-induced neuronal death. Nat Med 2005, 11:1322-1329.
169. Hill W.D., Hess D.C., Carroll J.E., Wakade C.G., Howard E.F., Chen Q., Cheng C., Martin-Studdard A., Waller J.L., Beswick R.A. The NF-kappaB inhibitor diethyldithiocarbamate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Res Bull 2001, 55:375-386.
170. Kim C.H., Kim J.H., Moon S.J., Hsu C.Y., Seo J.T., Ahn Y.S. Biphasic effects of dithiocarbamates on the activity of nuclear factor-kappaB. Eur J Pharmacol 2000, 392:133-136.
171. Misra H.P. Reaction of copper-zinc superoxide dismutase with diethyldithiocarbamate. J Biol Chem 1979, 254:11623-11628.
172. Ravati A., Ahlemeyer B., Becker A., Klumpp S., Krieglstein J. Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappaB. J Neurochem 2001, 78:909-919.
173. Kunz A., Park L., Abe T., Gallo E.F., Anrather J., Zhou P., Iadecola C. Neurovascular protection by ischemic tolerance: Role of nitric oxide and reactive oxygen species. J Neurosci 2007, 27:7083-7093.
174. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 2006, 7:437-448.
175. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
176. Paschen W., Gissel C., Althausen S., Doutheil J. Changes in interferon-regulatory factor-1 mRNA levels after transient ischemia in rat brain. Neuroreport 1998, 9:3147-3151.
177. Iadecola C., Alexander M., Nogawa S., Arachi E., Ross M.E. Inflammation-related genes and ischemic brain injury. Pharmacology of cerebral ischemia 2000 2000, 241-251. Medpharm Scientific Publishers, Stuttgart. J. Krieglstein, S. Klumpp (Eds.).
178. Yi J.H., Park S.W., Kapadia R., Vemuganti R. Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage. Neurochem Int 2007, 50:1014-1027.
179. Kapadia R., Tureyen K., Bowen K.K., Kalluri H., Johnson P.F., Vemuganti R. Decreased brain damage and curtailed inflammation in transcription factor CCAAT/enhancer binding protein beta knockout mice following transient focal cerebral ischemia. J Neurochem 2006, 98:1718-1731.
180. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26:244-251.
181. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
182. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270:12953-12956.
183. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130:685-696.
184. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006, 97:435-448.
185. Zhao Y., Patzer A., Gohlke P., Herdegen T., Culman J. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci 2005, 22:278-282.
186. Chu K., Lee S.T., Koo J.S., Jung K.H., Kim E.H., Sinn D.I., Kim J.M., Ko S.Y., Kim S.J., Song E.C., Kim M., Roh J.K. Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 2006, 1093:208-218.
187. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006, 24:1653-1663.
188. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23:6264-6271.
189. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med 2006, 41:579-589.
190. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
191. Zinn A., Felson S., Fisher E., Schwartzbard A. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 2008, 31:397-403.
192. Bahr R.D., Leino E.V., Christenson R.H. Prodromal unstable angina in acute myocardial infarction: Prognostic value of short- and long-term outcome and predictor of infarct size. Am Heart J 2000, 140:126-133.
193. Noda T., Minatoguchi S., Fujii K., Hori M., Ito T., Kanmatsuse K., Matsuzaki M., Miura T., Nonogi H., Tada M., Tanaka M., Fujiwara H. Evidence for the delayed effect in human ischemic preconditioning: Prospective multicenter study for preconditioning in acute myocardial infarction. J Am Coll Cardiol 1999, 34:1966-1974.
194. Ottani F., Galvani M., Ferrini D., Sorbello F., Limonetti P., Pantoli D., Rusticali F. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995, 91:291-297.
195. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
196. Kitagawa K., Matsumoto M., Tagaya M., Hata R., Ueda H., Niinobe M., Handa N., Fukunaga R., Kimura K., Mikoshiba K., et al. "Ischemic tolerance" phenomenon found in the brain. Brain Res 1990, 528:21-24.
197. Weih M., Kallenberg K., Bergk A., Dirnagl U., Harms L., Wernecke K.D., Einhaupl K.M. Attenuated stroke severity after prodromal TIA: A role for ischemic tolerance in the brain?. Stroke 1999, 30:1851-1854.
198. Moncayo J., de Freitas G.R., Bogousslavsky J., Altieri M., van Melle G. Do transient ischemic attacks have a neuroprotective effect?. Neurology 2000, 54:2089-2094.
199. Schobitz B., De Kloet E.R., Holsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol 1994, 44:397-432.
200. Ohtsuki T., Ruetzler C.A., Tasaki K., Hallenbeck J.M. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J Cereb Blood Flow Metab 1996, 16:1137-1142.
201. Song W., Furman B.L., Parratt J.R. Delayed protection against ischaemia-induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin. Br J Pharmacol 1996, 118:2157-2163.
202. Eising G.P., Mao L., Schmid-Schonbein G.W., Engler R.L., Ross J. Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. Cardiovasc Res 1996, 31:73-81.
203. Rowland R.T., Meng X., Cleveland J.C., Meldrum D.R., Harken A.H., Brown J.M. LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Am J Physiol 1997, 272:H2708-H2715.
204. Tasaki K., Ruetzler C.A., Ohtsuki T., Martin D., Nawashiro H., Hallenbeck J.M. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997, 748:267-270.
205. Puisieux F., Deplanque D., Pu Q., Souil E., Bastide M., Bordet R. Differential role of nitric oxide pathway and heat shock protein in preconditioning and lipopolysaccharide-induced brain ischemic tolerance. Eur J Pharmacol 2000, 389:71-78.
206. Bordet R., Deplanque D., Maboudou P., Puisieux F., Pu Q., Robin E., Martin A., Bastide M., Leys D., Lhermitte M., Dupuis B. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 2000, 20:1190-1196.
207. Wong G.H., Elwell J.H., Oberley L.W., Goeddel D.V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 1989, 58:923-931.
208. Eddy L.J., Goeddel D.V., Wong G.H. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 1992, 184:1056-1059.
209. Nawashiro H., Tasaki K., Ruetzler C.A., Hallenbeck J.M. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997, 17:483-490.
210. Ginis I., Jaiswal R., Klimanis D., Liu J., Greenspon J., Hallenbeck J.M. TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: The role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab 2002, 22:142-152.
211. Stenzel-Poore M.P., Stevens S.L., King J.S., Simon R.P. Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: A speculative synthesis. Stroke 2007, 38:680-685.
212. Sherman D.G. The Enlimomab Acute Stroke Trial: Final results. Neurology 1997, 48:A270. Investigators TEAST.
213. The Enlimomab Acute Stroke Trial: Final results. Cerebrovasc Dis 1998, 7(suppl 4):18. The Enlimomab Acute Stroke Trial Investigators.
214. Vuorte J., Lindsberg P.J., Kaste M., Meri S., Jansson S.E., Rothlein R., Repo H. Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J Immunol 1999, 162:2353-2357.
215. Zhang R.L., Zhang Z.G., Chopp M. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999, 30:624-629.
216. Zhang R., Powers C., Zhang Z., Chopp M. Infusion of intercellular adhesion molecule 1 antibody (18h) upregulates E- and P-selectinexpression during focal embolic cerebral ischemia in rats [abstract]. Stroke 1998, 29:282.
217. Furuya K., Takeda H., Azhar S., McCarron R.M., Chen Y., Ruetzler C.A., Wolcott K.M., DeGraba T.J., Rothlein R., Hugli T.E., del Zoppo G.J., Hallenbeck J.M. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study. Stroke 2001, 32:2665-2674.
218. Sughrue M.E., Mehra A., Connolly E.S., D'Ambrosio A.L. Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: A critical review of the literature. Inflamm Res 2004, 53:497-508.
219. Yenari M.A., Kunis D., Sun G.H., Onley D., Watson L., Turner S., Whitaker S., Steinberg G.K. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 1998, 153:223-233.
220. Krams M., Lees K.R., Hacke W., Grieve A.P., Orgogozo J.M., Ford G.A. Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003, 34:2543-2548.
221. Weiner H.L. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997, 18:335-343.
222. Chen Y., Inobe J., Marks R., Gonnella P., Kuchroo V.K., Weiner H.L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995, 376:177-180.
223. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
224. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
225. Faria A.M., Weiner H.L. Oral tolerance: Mechanisms and therapeutic applications. Adv Immunol 1999, 73:153-264.
226. Metzler B., Wraith D.C. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1996, 778:228-242.
227. Becker K.J., McCarron R.M., Ruetzler C., Laban O., Sternberg E., Flanders K.C., Hallenbeck J.M. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A 1997, 94:10873-10878.
228. Takeda H., Spatz M., Ruetzler C., McCarron R., Becker K., Hallenbeck J. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive, genetically stroke-prone rats. Stroke 2002, 33:2156-2163.
229. Alberts M.J., Bertels C., Dawson D.V. An analysis of time of presentation after stroke. JAMA 1990, 263:65-68.
230. Hayward N.J., Elliott P.J., Sawyer S.D., Bronson R.T., Bartus R.T. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996, 139:188-202.
231. Lapchak P.A., Araujo D.M., Song D., Zivin J.A. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioral deficits induced by reversible spinal cord ischemia. Stroke 2001, 32:1220-1225.
232. Kim E., Tolhurst A.T., Qin L.Y., Chen X.Y., Febbraio M., Cho S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. J Neurosci 2008, 28:4661-4670.
233. Norris J.W., Hachinski V.C. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986, 292:21-23.
234. Becker K.J. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002, 18(suppl 2):s18-s22.
235. Emsley H.C., Smith C.J., Georgiou R.F., Vail A., Hopkins S.J., Rothwell N.J., Tyrrell P.J. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005, 76:1366-1372.
236. Lampl Y., Boaz M., Gilad R., Lorberboym M., Dabby R., Rapoport A., Anca-Hershkowitz M., Sadeh M. Minocycline treatment in acute stroke: An open-label, evaluator-blinded study. Neurology 2007, 69:1404-1410.
237. Schilling M., Besselmann M., Leonhard C., Mueller M., Ringelstein E.B., Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: A study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2003, 183:25-33.
238. Abe T., Shimamura M., Jackman K. Key role of CD36 in toll-like receptor 2 signaling in cerebral ischemia. Stroke 2010, 41:898-904.
239. Fagan S.C., Waller J.L., Nichols F.T. Minocycline to improve neurologic outcome in stroke (MINOS). A dose finding study. Stroke 2010, 41. 2283.